Oliver Dolly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2807381/publications.pdf

Version: 2024-02-01

238 papers 13,245 citations

61 h-index 30081 103 g-index

241 all docs

241 docs citations

times ranked

241

5395 citing authors

#	Article	IF	CITATIONS
1	Inactivation properties of voltage-gated K+ channels altered by presence of \hat{l}^2 -subunit. Nature, 1994, 369, 289-294.	27.8	833
2	Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3200-3205.	7.1	601
3	Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature, 1984, 307, 457-460.	27.8	318
4	Evaluation of the Therapeutic Usefulness of Botulinum Neurotoxin B, C1, E, and F Compared with the Long Lasting Type A. Journal of Biological Chemistry, 2003, 278, 1363-1371.	3.4	308
5	Botulinum Neurotoxin C1 Cleaves both Syntaxin and SNAP-25 in Intact and Permeabilized Chromaffin Cells:  Correlation with Its Blockade of Catecholamine Release. Biochemistry, 1996, 35, 2630-2636.	2.5	249
6	Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis Journal of Cell Biology, 1986, 103, 535-544.	5 . 2	246
7	Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves Journal of Cell Biology, 1986, 103, 521-534.	5.2	236
8	Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. Journal of Cell Science, 2007, 120, 2864-2874.	2.0	230
9	The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience, 1982, 7, 997-1006.	2.3	218
10	Activation of TRPV1 Mediates Calcitonin Gene-Related Peptide Release, Which Excites Trigeminal Sensory Neurons and Is Attenuated by a Retargeted Botulinum Toxin with Anti-Nociceptive Potential. Journal of Neuroscience, 2009, 29, 4981-4992.	3.6	207
11	Central action of dendrotoxin: selective reduction of a transient K conductance in hippocampus and binding to localized acceptors Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 493-497.	7.1	201
12	Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. Journal of Biological Chemistry, 1992, 267, 21338-43.	3.4	201
13	The structure and mode of action of different botulinum toxins. European Journal of Neurology, 2006, 13, 1-9.	3.3	196
14	Synaptic Transmission: Inhibition of Neurotransmitter Release by Botulinum Toxins. Headache, 2003, 43, 16-24.	3.9	191
15	Primary structure of a beta subunit of alpha-dendrotoxin-sensitive K+ channels from bovine brain Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 1637-1641.	7.1	178
16	Glial heterogeneity in expression of the inwardly rectifying K+ channel, Kir4.1, in adult rat CNS., 2000, 30, 362-372.		158
17	Antibodies specific for distinct Kv subunits unveil a heterooligomeric basis for subtypes of .alphadendrotoxin-sensitive potassium channels in bovine brain. Biochemistry, 1994, 33, 1617-1623.	2.5	147
18	Brain and muscle nicotinic acetylcholine receptors are different but homologous proteins Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 5208-5212.	7.1	145

#	Article	IF	CITATIONS
19	Oligomeric properties of .alphadendrotoxin-sensitive potassium ion channels purified from bovine brain. Biochemistry, 1992, 31, 11084-11088.	2.5	136
20	Subunit Combinations Defined for K+ Channel Kv1 Subtypes in Synaptic Membranes from Bovine Brain. Biochemistry, 1997, 36, 8195-8201.	2.5	136
21	Subunit Composition of Kv1 Channels in Human CNS. Journal of Neurochemistry, 2002, 73, 849-858.	3.9	133
22	Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Molecular and Cellular Neurosciences, 2003, 22, 454-466.	2.2	133
23	Acetylcholine Receptor and Ion Conductance Modulator Sites at the Murine Neuromuscular Junction: Evidence from Specific Toxin Reactions. Proceedings of the National Academy of Sciences of the United States of America, 1973, 70, 949-953.	7.1	130
24	Mast cell degranulating peptide and dendrotoxin selectively inhibit a fast-activating potassium current and bind to common neuronal proteins. Neuroscience, 1987, 23, 893-902.	2.3	119
25	Neurotransmitter release is blocked intracellularly by botulinum neurotoxin, and this requires uptake of both toxin polypeptides by a process mediated by the larger chain Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 4090-4094.	7.1	119
26	Vesicle exocytosis stimulated by \hat{l}_{\pm} -latrotoxin is mediated by latrophilin and requires both external and stored Ca2+. EMBO Journal, 1998, 17, 3909-3920.	7.8	119
27	Differences in the Protease Activities of Tetanus and Botulinum B Toxins Revealed by the Cleavage of Vesicle-Associated Membrane Protein and Various Sized Fragments. Biochemistry, 1994, 33, 15365-15374.	2.5	118
28	Characterization of the Inhibitory Action of Botulinum Neurotoxin Type A on the Release of Several Transmitters from Rat Cerebrocortical Synaptosomes. Journal of Neurochemistry, 1988, 50, 1808-1816.	3.9	116
29	Selective location of acceptors for botulinum neurotoxin a in the central and peripheral nervous systems. Neuroscience, 1987, 23, 767-779.	2.3	114
30	Dendrotoxin acceptor from bovine synaptic plasma membranes. Binding properties, purification and subunit composition of a putative constituent of certain voltage-activated K+ channels. Biochemical Journal, 1989, 257, 899-903.	3.7	114
31	Radioiodination of Botulinum Neurotoxin Type A with Retention of Biological Activity and Its Binding to Brain Synaptosomes. FEBS Journal, 1983, 131, 437-445.	0.2	113
32	Molecular properties of voltage-gated K+ channels. Journal of Bioenergetics and Biomembranes, 1996, 28, 231-253.	2.3	109
33	Stoichiometry of the Ligand-Binding Sites in the Acetylcholine-Receptor Oligomer from Muscle and from Electric Organ. Measurement by Affinity Alkylation with Bromoacetylcholine. FEBS Journal, 1980, 109, 495-505.	0.2	107
34	Protein Kinase B Stimulates the Translocation of GLUT4 but Not GLUT1 or Transferrin Receptors in 3T3-L1 Adipocytes by a Pathway Involving SNAP-23, Synaptobrevin-2, and/or Cellubrevin. Journal of Biological Chemistry, 1999, 274, 28087-28095.	3.4	107
35	Novel Chimeras of Botulinum Neurotoxins A and E Unveil Contributions from the Binding, Translocation, and Protease Domains to Their Functional Characteristics. Journal of Biological Chemistry, 2008, 283, 16993-17002.	3.4	102
36	TNFα induces co-trafficking of TRPV1/TRPA1 in VAMP1-containing vesicles to the plasmalemma via Munc18–1/syntaxin1/SNAP-25 mediated fusion. Scientific Reports, 2016, 6, 21226.	3.3	102

3

#	Article	IF	CITATIONS
37	Preparation of Neurotoxic 3H-β-Bungarotoxin: Demonstration of Saturable Binding to Brain Synapses and Its Inhibition by Toxin I. FEBS Journal, 2005, 128, 267-276.	0.2	100
38	Botulinum neurotoxin type B. Its purification, radioiodination and interaction with rat-brain synaptosomal membranes. FEBS Journal, 1986, 154, 409-416.	0.2	96
39	Alpha-dendrotoxin acceptor from bovine brain is a K+ channel protein. Evidence from the N-terminal sequence of its larger subunit. Journal of Biological Chemistry, 1990, 265, 20094-20097.	3.4	93
40	Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon, 2003, 42, 461-469.	1.6	88
41	Size of acetylcholine receptors in the membrane. An improved version of the radiation inactivation method. Biochemistry, 1982, 21, 2210-2217.	2.5	87
42	Dendrotoxin, 4-Aminopyridine, and ?-Bungarotoxin Act at Common Loci but by Two Distinct Mechanisms to Induce Ca2+-Dependent Release of Glutamate from Guinea-Pig Cerebrocortical Synaptosomes. Journal of Neurochemistry, 1989, 52, 201-206.	3.9	86
43	A Dileucine in the Protease of Botulinum Toxin A Underlies Its Long-lived Neuroparalysis. Journal of Biological Chemistry, 2011, 286, 6375-6385.	3.4	78
44	Involvement of neuronal acceptors for dendrotoxin in its convulsive action in rat brain. Biochemical Journal, 1986, 237, 397-404.	3.7	77
45	Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes. FEBS Journal, 1987, 165, 675-681.	0.2	77
46	Alpha-dendrotoxin acceptor from bovine brain is a K+ channel protein. Evidence from the N-terminal sequence of its larger subunit. Journal of Biological Chemistry, 1990, 265, 20094-7.	3.4	77
47	Nicotinic acetylcholine receptor from chick optic lobe Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 1321-1325.	7.1	75
48	Involvement of the constituent chains of botulinum neurotoxins A and B in the blockade of neurotransmitter release. FEBS Journal, 1988, 177, 683-691.	0.2	75
49	Norepinephrine exocytosis stimulated by α–latrotoxin requires both external and stored Ca 2+ and is mediated by latrophilin, G proteins and phospholipase C. Philosophical Transactions of the Royal Society B: Biological Sciences, 1999, 354, 379-386.	4.0	7 5
50	Rescue of Exocytosis in Botulinum Toxin A-poisoned Chromaffin Cells by Expression of Cleavage-resistant SNAP-25. Journal of Biological Chemistry, 1999, 274, 36897-36904.	3.4	73
51	Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeuticsâ ⁻ †. Current Opinion in Pharmacology, 2009, 9, 326-335.	3.5	71
52	alpha Subunit compositions of Kv1.1-containing K+ channel subtypes fractionated from rat brain using dendrotoxins. FEBS Journal, 1999, 263, 230-237.	0.2	70
53	Botulinum A Like Type B and Tetanus Toxins Fulfils Criteria for Being a Zinc-Dependent Protease. Journal of Neurochemistry, 1993, 61, 2338-2341.	3.9	69
54	Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. Current Opinion in Pharmacology, 2012, 12, 100-108.	3.5	69

#	Article	IF	CITATIONS
55	Light chain of botulinum neurotoxin is active in mammalian motor nerve terminals when delivered via liposomes. FEBS Letters, 1990, 277, 171-174.	2.8	68
56	A Single Mutation in the Recombinant Light Chain of Tetanus Toxin Abolishes Its Proteolytic Activity and Removes the Toxicity Seen after Reconstitution with Native Heavy Chain. Biochemistry, 1994, 33, 7014-7020.	2.5	65
57	Episodic Ataxia Type-1 Mutations in the Kv1.1 Potassium Channel Display Distinct Folding and Intracellular Trafficking Properties. Journal of Biological Chemistry, 2001, 276, 49427-49434.	3.4	65
58	Studies of the oestrogen sulphatase and arylsulphatase C activities of rat liver. Biochemical Journal, 1972, 128, 337-345.	3.1	64
59	Two acceptor sub-types for dendrotoxin in chick synaptic membranes distinguishable by beta-bungarotoxin. FEBS Journal, 1986, 156, 609-617.	0.2	64
60	Identification of residues in dendrotoxin K responsible for its discrimination between neuronal K+ channels containing Kv1.1 and 1.2 alpha subunits. FEBS Journal, 1999, 263, 222-229.	0.2	64
61	A role for the interchain disulfide or its participating thiols in the internalization of botulinum neurotoxin A revealed by a toxin derivative that binds to ecto-acceptors and inhibits transmitter release intracellularly. Journal of Biological Chemistry, 1993, 268, 20838-44.	3.4	64
62	Botulinum A and the light chain of tetanus toxins inhibit distinct stages of Mg . ATP-dependent catecholamine exocytosis from permeabilised chromaffin cells. FEBS Journal, 1994, 222, 325-333.	0.2	63
63	The mechanism of action of \hat{l}^2 -bungarotoxin at the presynaptic plasma membrane. Biochemical Journal, 1986, 233, 519-523.	3.7	62
64	Ca2+-dependent noradrenaline release from permeabilised PC 12 cells is blocked by botulinum neurotoxin A or its light chain. FEBS Letters, 1990, 261, 323-326.	2.8	61
65	Production of seizures and brain damage in rats by α-dendrotoxin, a selective K+ channel blocker. Neuroscience Letters, 1992, 139, 34-40.	2.1	59
66	Prominent location of a K+ channel containing the \hat{l}_{\pm} subunit KV 1.2 in the basket cell nerve terminals of rat cerebellum. Neuroscience, 1993, 57, 1039-1045.	2.3	59
67	Putative benzodiazepine receptor: A protein solubilised from brain. FEBS Letters, 1979, 104, 149-153.	2.8	58
68	Solubilization and physical characterization of acceptors for dendrotoxin and .betabungarotoxin from synaptic membranes of rat brain. Biochemistry, 1988, 27, 6814-6820.	2.5	58
69	K+ channel sub-types in rat brain: Characteristic locations revealed using \hat{l}^2 -bungarotoxin, \hat{l}_{\pm} - and \hat{l} -dendrotoxins. Neuroscience, 1991, 40, 29-39.	2.3	58
70	Purification and characterization of an acetylcholine receptor from mammalian skeletal muscle. Biochemistry, 1977, 16, 5053-5060.	2.5	56
71	Botulinum Neurotoxin B Inhibits Insulin-Stimulated Glucose Uptake into 3T3-L1 Adipocytes and Cleaves Cellubrevin Unlike Type A Toxin Which Failed To Proteolyze the SNAP-23 Presentâ€. Biochemistry, 1997, 36, 5719-5728.	2.5	55
72	Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP-25 and Neurotoxicity after Reconstitution with the Heavy Chain. Biochemistry, 1995, 34, 15175-15181.	2.5	54

#	Article	IF	Citations
73	Importance of Two Adjacent C-terminal Sequences of SNAP-25 in Exocytosis from Intact and Permeabilized Chromaffin Cells Revealed by Inhibition with Botulinum Neurotoxins A and Eâ \in . Biochemistry, 1997, 36, 3061-3067.	2.5	53
74	Extravesicular intraneuronal migration of internalized botulinum neurotoxins without detectable inhibition of distal neurotransmission. Biochemical Journal, 2012, 441, 443-452.	3.7	53
75	Predominant expression of Kv1.3 voltage-gated K+ channel subunit in rat prostate cancer cell lines: electrophysiological, pharmacological and molecular characterisation. Pflugers Archiv European Journal of Physiology, 2003, 446, 559-571.	2.8	52
76	Molecular sizes of benzodiazepine receptors and the interacting gaba receptors in the membrane are identical. FEBS Letters, 1981, 126, 309-312.	2.8	50
77	Preparation and Characterisation of Homogeneous Neurotoxin Type A from <i>Clostridium botulinum</i> . FEBS Journal, 1982, 122, 493-500.	0.2	50
78	Distribution in the rat central nervous system of acceptor sub-types for dendrotoxin, a K+ channel probe. Neuroscience, 1989, 29, 347-361.	2.3	49
79	Dendritic SNAREs add a new twist to the old neuron theory. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19113-19120.	7.1	48
80	Identification of the Neuronal Acceptor in Bovine Cortex for Ammodytoxin C, a Presynaptically Neurotoxic Phospholipase A2. Biochemistry, 1994, 33, 13938-13945.	2.5	47
81	Identification by cross-linking of a neuronal acceptor protein for dendrotoxin, a convulsant polypeptide. FEBS Letters, 1984, 174, 116-122.	2.8	46
82	Ultrastructural Localization of a Voltage-gated K+Channel a Subunit (Kv1.2) in the Rat Cerebellum. European Journal of Neuroscience, 1996, 8, 688-699.	2.6	46
83	Site-Directed Mutagenesis of Dendrotoxin K Reveals Amino Acids Critical for Its Interaction with Neuronal K+Channelsâ€. Biochemistry, 1997, 36, 7690-7696.	2.5	46
84	Excitatory Cholinergic and Purinergic Signaling in Bladder Are Equally Susceptible to Botulinum Neurotoxin A Consistent with Co-Release of Transmitters from Efferent Fibers. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 1080-1086.	2.5	46
85	The effects of in vitro application of purified botulinum neurotoxin at mouse motor nerve terminals Journal of Physiology, 1987, 386, 475-484.	2.9	45
86	Disruption of Myelin Leads to Ectopic Expression of KV1.1 Channels with Abnormal Conductivity of Optic Nerve Axons in a Cuprizone-Induced Model of Demyelination. PLoS ONE, 2014, 9, e87736.	2.5	45
87	Distinctive role of KV1.1 subunit in the biology and functions of low threshold K+ channels with implications for neurological disease., 2016, 159, 93-101.		45
88	Solubilization from skeletal muscle of two components that specifically bind \hat{l}_{\pm} -bungarotoxin. Biochemical and Biophysical Research Communications, 1973, 51, 205-213.	2.1	44
89	Botulinum type F neurotoxin. Large-scale purification and characterization of its binding to rat cerebrocortical synaptosomes. Biochemical Journal, 1990, 268, 123-128.	3.7	44
90	Bioenergetic actions of \hat{l}^2 -bungarotoxin, dendrotoxin and bee-venom phospholipase A2 on guinea-pig synaptosomes. Biochemical Journal, 1985, 229, 653-662.	3.7	43

#	Article	IF	Citations
91	Latrophilin, Neurexin, and Their Signaling-deficient Mutants Facilitate α-Latrotoxin Insertion into Membranes but Are Not Involved in Pore Formation. Journal of Biological Chemistry, 2000, 275, 41175-41183.	3.4	42
92	Nicotinic acetylcholine receptors: An overview. Biochemical Pharmacology, 1984, 33, 841-858.	4.4	41
93	Tetanus Toxin Inhibits Neuroexocytosis Even When Its Zn2+-dependent Protease Activity Is Removed. Journal of Biological Chemistry, 1995, 270, 31386-31390.	3.4	41
94	Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain. Journal of Neuroscience Research, 1996, 44, 263-271.	2.9	41
95	Composition of acetylcholine receptor protein from skeletal muscle. Nature, 1978, 274, 283-284.	27.8	40
96	Complete purification of \hat{l}^2 -bungarotoxin. Characterization of its action and that of tityustoxin on synaptosomal accumulation and release of acetylcholine. Biochimica Et Biophysica Acta - Biomembranes, 1980, 596, 81-93.	2.6	40
97	Probing the process of transmitter release with botulinum and tetanus neurotoxins. Seminars in Neuroscience, 1994, 6, 149-158.	2.2	40
98	Synaptic vesicle cycle and amyloid \hat{l}^2 : Biting the hand that feeds. Alzheimer's and Dementia, 2018, 14, 502-513.	0.8	40
99	Distinct Exocytotic Responses of Intact and Permeabilised Chromaffin Cells After Cleavage of the 25-kDa Synaptosomal-Associated Protein (SNAP-25) or Synaptobrevin by Botulinum Toxin A or B. FEBS Journal, 1996, 236, 877-886.	0.2	39
100	Voltage-gated K+ Channel from Mammalian Brain: 3D Structure at $18\tilde{A}$ of the Complete $(\hat{l}\pm)4(\hat{l}^2)4$ Complex. Journal of Molecular Biology, 2003, 326, 1005-1012.	4.2	39
101	Characterization of recombinant tetanus toxin derivatives suitable for vaccine development. Infection and Immunity, 1995, 63, 3218-3221.	2.2	39
102	Heterologous combinations of heavy and light chains from botulinum neurotoxin A and tetanus toxin inhibit neurotransmitter release in Aplysia. Journal of Biological Chemistry, 1991, 266, 9580-5.	3.4	39
103	Interactions between discrete neuronal membrane binding sites for the putative K+-channel ligands beta-bungarotoxin, dendrotoxin and mast-cell-degranulating peptide. FEBS Journal, 1989, 178, 771-778.	0.2	38
104	Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators. FEBS Journal, 2011, 278, 4454-4466.	4.7	38
105	Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B. Biochemical Journal, 2012, 444, 59-67.	3.7	38
106	Acetylcholine Receptor from Mammalian Skeletal Muscle. Oligomeric Forms and Their Subunit Structures. FEBS Journal, 1981, 116, 143-153.	0.2	37
107	Microtubule-Dissociating Drugs and A23187 Reveal Differences in the Inhibition of Synaptosomal Transmitter Release by Botulinum Neurotoxins Types A and B. Journal of Neurochemistry, 1991, 56, 827-835.	3.9	37
108	Cloning and functional expression of dendrotoxin K from black mamba, a potassium channel blocker. Biochemistry, 1993, 32, 5692-5697.	2.5	37

#	Article	IF	Citations
109	Properties of monoclonal antibodies to nicotinic acetylcholine receptor from chick muscle. FEBS Journal, 1984, 138, 53-61.	0.2	36
110	Distribution of acceptors for $\tilde{\text{A}}\ddot{\text{Y}}$ -bungarotoxin in the central nervous system of the rat. Brain Research, 1988, 441, 127-138.	2.2	36
111	Blockade by dendrotoxin homologues of voltageâ€dependent K ⁺ currents in cultured sensory neurones from neonatal rats. British Journal of Pharmacology, 1994, 113, 959-967.	5.4	36
112	Peripheral and central nicotinic ACh receptors â€" how similar are they?. Trends in Neurosciences, 1982, 5, 325-327.	8.6	35
113	Characteristics of Brain Kv1 Channels Tailored to Mimic Native Counterparts by Tandem Linkage of α Subunits. Journal of Biological Chemistry, 2002, 277, 16376-16382.	3.4	35
114	Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis. FASEB Journal, 2012, 26, 5035-5048.	0.5	35
115	The acetylcholine receptor and the ionic conductance modulation system of skeletal muscle. Experimental Neurology, 1975, 48, 1-28.	4.1	34
116	Blockade by Botulinum Neurotoxin B of Catecholamine Release from Adrenochromaffin Cells Correlates with Its Cleavage of Synaptobrevin and a Homolog Present on the Granules. Biochemistry, 1995, 34, 5494-5503.	2.5	34
117	Reconstitution of a partially purified endplate acetylcholine receptor preparation in lipid bilayer membranes. Biochemical and Biophysical Research Communications, 1973, 54, 607-613.	2.1	33
118	A sensitive and useful radioimmunoassay for neurotoxin and its haemagglutinin complex from Clostridium botulinum. Toxicon, 1985, 23, 235-246.	1.6	33
119	Characterization of monoclonal antibodies against voltage-dependent potassium channels raised using .alphadendrotoxin acceptors purified from bovine brain. Biochemistry, 1992, 31, 12297-12303.	2.5	33
120	The inactivation behaviour of voltage-gated K-channels may be determined by association of \hat{l}_{\pm} - and \hat{l}_{\pm} -subunits. Journal of Physiology (Paris), 1994, 88, 173-180.	2.1	32
121	Oligomeric and subunit structures of neuronal voltage-sensitive K+ channels. Biochemical Society Transactions, 1994, 22, 473-478.	3.4	32
122	Recombinant Forms of Tetanus Toxin Engineered for Examining and Exploiting Neuronal Trafficking Pathways. Journal of Biological Chemistry, 2001, 276, 31394-31401.	3.4	32
123	Multiple forms of dipeptidases in normal human intestinal mucosa and in mucosa from children with coeliac disease. Clinica Chimica Acta, 1969, 26, 555-558.	1.1	31
124	Concatemers of brain Kv1 channel \hat{l}_{\pm} subunits that give similar K+ currents yield pharmacologically distinguishable heteromers. Neuropharmacology, 2007, 53, 272-282.	4.1	31
125	Targeted delivery into motor nerve terminals of inhibitors for SNAREâ€cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin. FEBS Journal, 2012, 279, 2555-2567.	4.7	31
126	Multiple Domains of Botulinum Neurotoxin Contribute to Its Inhibition of Transmitter Release in Aplysia Neurons. Journal of Biological Chemistry, 1989, 264, 21928-21933.	3.4	31

#	Article	IF	CITATIONS
127	Affinity labelling by bromoacetylcholine of a characteristic subunit in the acetylcholine receptor from muscle and Torpedo electric organ. FEBS Letters, 1979, 108, 20-24.	2.8	30
128	Preferential action of \hat{l}^2 -bungarotoxin at nerve terminal regions in the hippocampus. Neuroscience Letters, 1982, 30, 321-327.	2.1	30
129	Localization of sites for 125I-labelled botulinum neurotoxin at murine neuromuscular junction and its binding to rat brain synaptosomes. Toxicon, 1982, 20, 141-148.	1.6	30
130	Inhibition of transmitter release by botulinum neurotoxin A. Contribution of various fragments to the intoxication process. FEBS Journal, 1989, 185, 197-203.	0.2	30
131	Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment. BJU International, 2007, 100, 070907033641006-???.	2.5	30
132	<scp>SNAP</scp> â€23 and <scp>VAMP</scp> â€3 contribute to the release of <scp>IL</scp> â€6 and <scp>TNF</scp> î± from a human synovial sarcoma cell line. FEBS Journal, 2014, 281, 750-765.	4.7	30
133	Two Protein Trafficking Processes at Motor Nerve Endings Unveiled by Botulinum Neurotoxin E. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 410-418.	2.5	29
134	Binding of perhydro-histrionicotoxin to the postsynaptic membrane of skeletal muscle in relation to its blockage of acetylcholine-induced depolarization. Molecular Pharmacology, 1977, 13, 1-14.	2.3	29
135	How to Validate a Heteromeric Ion Channel Drug Target: Assessing Proper Expression of Concatenated Subunits. Journal of General Physiology, 2008, 131, 415-420.	1.9	28
136	Evidence for the Induction of Repetitive Action Potentials in Synaptosomes by K ⁺ â€Channel Inhibitors: An Analysis of Plasma Membrane Ion Fluxes. Journal of Neurochemistry, 1996, 67, 389-397.	3.9	27
137	Amyloid Plaques of Alzheimer's Disease as Hotspots of Glutamatergic Activity. Neuroscientist, 2019, 25, 288-297.	3.5	27
138	Complete purification of the acetylcholine receptor protein from mammalian muscle. FEBS Letters, 1975, 57, 267-271.	2.8	26
139	Potassium channelsâ€"what can the protein chemistry contribute?. Trends in Neurosciences, 1988, 11, 186-188.	8.6	26
140	Characterisation of Binding Sites for ?-Dendrotoxin in Guinea-Pig Synaptosomes: Relationship to Acceptors for the K+-Channel Probe ?-Dendrotoxin. Journal of Neurochemistry, 1990, 54, 343-346.	3.9	26
141	Innocuous full-length botulinum neurotoxin targets and promotes the expression of lentiviral vectors in central and autonomic neurons. Gene Therapy, 2011, 18, 656-665.	4.5	26
142	Biochemical and Electrophysiological Demonstrations of the Actions of ?-Bungarotoxin on Synapses in Brain. Journal of Neurochemistry, 1982, 39, 543-550.	3.9	25
143	Recreation of Neuronal Kv1 Channel Oligomers by Expression in Mammalian Cells Using Semliki Forest Virus. Biochemistry, 1999, 38, 16766-16776.	2.5	25
144	A Late Phase of Exocytosis from Synaptosomes Induced by Elevated [Ca2+]i Is Not Blocked by Clostridial Neurotoxins. Journal of Neurochemistry, 2008, 74, 1979-1988.	3.9	25

#	Article	IF	CITATIONS
145	Arrangement of Kv1 \hat{l}_{\pm} subunits dictates sensitivity to tetraethylammonium. Journal of General Physiology, 2010, 136, 273-282.	1.9	25
146	Multiple domains of botulinum neurotoxin contribute to its inhibition of transmitter release in Aplysia neurons. Journal of Biological Chemistry, 1989, 264, 21928-33.	3.4	25
147	Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light-chain epitopes. FEBS Journal, 1994, 219, 161-169.	0.2	24
148	Acetylcholine and GABA Receptors: Subunits of Central and Peripheral Receptors and Their Encoding Nucleic Acids. Cold Spring Harbor Symposia on Quantitative Biology, 1983, 48, 109-124.	1.1	24
149	Effects of \hat{I}^2 -bungarotoxin and tityustoxin on accumulation of putative amino acid neurotransmitters by rat cortex synaptosomes. Neuroscience, 1980, 5, 135-143.	2.3	23
150	Tritiation of \hat{l}_{\pm} -bungarotoxin with N-succinimidyl [2,3-3H] propionate. A useful reagent for labelling proteins. Biochemical Journal, 1981, 193, 919-923.	3.7	23
151	N-methyl-d-aspartate and nonn-methyl-d-aspartate receptors mediate seizures and CA1 hippocampal damage induced by dendrotoxin-K in rats. Neuroscience, 1996, 71, 613-624.	2.3	23
152	Chapter 3: Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A. Neurourology and Urodynamics, 2014, 33, S14-20.	1.5	23
153	Similarity of Acetylcholine Receptors of Denervated, Innervated and Embryonic Chicken Muscles. 1. Molecular Species and Their Purification. FEBS Journal, 1982, 126, 465-472.	0.2	22
154	Similarity of Acetylcholine Receptors of Denervated, Innervated and Embryonic Chicken Muscles. 2. Subunit Compositions. FEBS Journal, 1982, 126, 473-479.	0.2	22
155	Modification of rat brain Kv1.4 channel gating by association with accessory Kv \hat{l}^2 1.1 and \hat{l}^2 2.1 subunits. Pflugers Archiv European Journal of Physiology, 1997, 435, 43-54.	2.8	22
156	Botulinum neurotoxin and dendrotoxin as probes for studies on transmitter release. Journal De Physiologie, 1984, 79, 280-303.	0.2	22
157	Molecular components required for resting and stimulated endocytosis of botulinum neurotoxins by glutamatergic and peptidergic neurons. FASEB Journal, 2013, 27, 3167-3180.	0.5	21
158	Internalization and retrograde axonal trafficking of tetanus toxin in motor neurons and trans-synaptic propagation at central synapses exceed those of its C-terminal-binding fragments. Brain Structure and Function, 2015, 220, 1825-1838.	2.3	21
159	Porphyrin derivatives as potent and selective blockers of neuronal Kv1 channels. Chemical Communications, 2015, 51, 1066-1069.	4.1	21
160	A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain. Neuropharmacology, 2017, 118, 223-232.	4.1	21
161	Differences in the multiple step process of inhibition of neurotransmitter release induced by tetanus toxin and botulinum neurotoxins type A and B atAplysia synapses. Neuroscience, 1996, 70, 567-576.	2.3	20
162	Cloning of a bovine voltage-gated K+channel gene utilising partial amino acid sequence of a dendrotoxin-binding protein from brain cortex. FEBS Letters, 1992, 302, 31-34.	2.8	19

#	Article	IF	Citations
163	A defined heteromeric K $<$ sub $>$ V $<$ /sub $>$ 1 channel stabilizes the intrinsic pacemaking and regulates the output of deep cerebellar nuclear neurons to thalamic targets. Journal of Physiology, 2013, 591, 1771-1791.	2.9	19
164	Selective Cleavage of SNAREs in Sensory Neurons Unveils Protein Complexes Mediating Peptide Exocytosis Triggered by Different Stimuli. Molecular Neurobiology, 2014, 50, 574-588.	4.0	19
165	A SNAP-25 cleaving chimera of botulinum neurotoxin /A and /E prevents TNF뱉^'induced elevation of the activities of native TRP channels on early postnatal rat dorsal root ganglion neurons. Neuropharmacology, 2018, 138, 257-266.	4.1	19
166	Dendrotoxin and charybdotoxin increase the cytosolic concentration of free Ca2+ in cerebrocortical synaptosomes: An effect not shared by apamin. FEBS Letters, 1989, 255, 159-162.	2.8	18
167	Preparation and characterisation of homogeneous neurotoxin type A from Clostridium botulinum. Its inhibitory action on neuronal release of acetylcholine in the absence and presence of beta-bungarotoxin. FEBS Journal, 1982, 122, 493-500.	0.2	18
168	Monoclonal and polyclonal antibodies against dendrotoxin: Their effects on its convulsive activity and interaction with neuronal acceptors. Neurochemistry International, 1986, 9, 11-22.	3.8	17
169	Hippocampal damage produced in rats by α-dendrotoxin—a selective K+ channel blocker—involves non-NMDA receptor activation. Neurochemistry International, 1994, 24, 81-90.	3.8	17
170	A Functional Spliced-Variant of \hat{I}^2 2 Subunit of Kv1 Channels in C6 Glioma Cells and Reactive Astrocytes from Rat Lesioned Cerebellum. Biochemistry, 1999, 38, 16984-16992.	2.5	17
171	Pharmacological characteristics of Kv1.1- and Kv1.2-containing channels are influenced by the stoichiometry and positioning of their $\hat{l}\pm$ subunits. Biochemical Journal, 2013, 454, 101-108.	3.7	17
172	Targeted delivery of a SNARE protease to sensory neurons using a single chain antibody (scFv) against the extracellular domain of P2X3 inhibits the release of a pain mediator. Biochemical Journal, 2014, 462, 247-256.	3.7	17
173	Further studies on multiple forms of peptidases in mammalian tissues including intestinal mucosa from children with treated and untreated coeliac disease. Clinica Chimica Acta, 1971, 31, 55-62.	1.1	16
174	Affinity of cholinergic ligands for the partially purified acetylcholine receptor from mammalian skeletal muscle. FEBS Letters, 1974, 46, 145-148.	2.8	16
175	Synaptic binding sites in brain for [3H]β-bungarotoxin — A specific probe that perturbs transmitter release. Neurochemistry International, 1983, 5, 487-496.	3.8	16
176	Neurobiology and therapeutic applications of neurotoxins targeting transmitter release., 2019, 193, 135-155.		16
177	Binding of ?-bungarotoxin and cholinergic ligands to acetylcholine receptors in the membrane of skeletal muscle. Cell Biology International Reports, 1977, 1, 99-106.	0.6	15
178	Electrophysiological analysis of the presynaptic action of \hat{l}^2 -bungarotoxin in the central nervous system. Toxicon, 1982, 20, 121-127.	1.6	15
179	Homologues of a K+ channel blocker α-dendrotoxin: characterization of synaptosomal binding sites and their coupling to elevation of cytosolic free calcium concentration. Neurochemistry International, 1990, 16, 105-112.	3.8	15
180	Microtubules and Microfilaments Participate in the Inhibition of Synaptosomal Noradrenaline Release by Tetanus Toxin. Journal of Neurochemistry, 1997, 68, 649-658.	3.9	15

#	Article	IF	Citations
181	Therapeutic effectiveness of botulinum neurotoxin A: Potent blockade of autonomic transmission by targeted cleavage of only the pertinent SNAP-25. Neuropharmacology, 2013, 70, 287-295.	4.1	15
182	Improved Lentiviral Transduction of ALS Motoneurons <i>iin Vivo</i> via Dual Targeting. Molecular Pharmaceutics, 2013, 10, 4195-4206.	4.6	15
183	Effects of \hat{I}^2 -Bungarotoxin and Tityustoxin on Uptake and Release of Neurotransmitters. Biochemical Society Transactions, 1978, 6, 652-654.	3.4	14
184	Molecular Forms of the Acetylcholine Receptor from Vertebrate Muscles and Torpedo Electric Organ. Interactions with Specific Ligands. FEBS Journal, 1981, 116, 155-163.	0.2	14
185	Identification and localization of low-molecular-mass GTP-binding proteins associated with synaptic vesicles and other membranes. Biochimica Et Biophysica Acta - Biomembranes, 1990, 1026, 99-104.	2.6	14
186	Insights into a basis for incomplete inhibition by botulinum toxin A of Ca2+-evoked exocytosis from permeabilised chromaffin cells. Toxicology, 2002, 181-182, 249-253.	4.2	14
187	Metabolism of sodium oestrone [35S]sulphate in the rat. Biochemical Journal, 1971, 123, 261-266.	3.1	13
188	Seizures and Hippocampal Damage Produced by Dendrotoxin-K in Rats Is Prevented by the 21-Aminosteroid U-74389G. Experimental Neurology, 1997, 147, 204-210.	4.1	13
189	Transglutaminase participates in the blockade of neurotransmitter release by tetanus toxin: evidence for a novel biological function. Amino Acids, 2010, 39, 257-269.	2.7	13
190	Circumventing Brain Barriers: Nanovehicles for Retroaxonal Therapeutic Delivery. Trends in Molecular Medicine, 2016, 22, 983-993.	6.7	13
191	Size and Molecular Properties of the Acetylcholine-Receptor Protein of Muscle. Biochemical Society Transactions, 1978, 6, 649-651.	3.4	12
192	Differences in the temperature dependencies of uptake of botulinum and tetanus toxins in Aplysia neurons. Neuroscience Letters, 1992, 139, 289-292.	2.1	12
193	Adeno-Associated Virus Transfer of a Gene Encoding SNAP-25 Resistant to Botulinum Toxin A Attenuates Neuromuscular Paralysis Associated with Botulism. Journal of Neuroscience, 2008, 28, 3683-3688.	3.6	12
194	Cloning and expression of mamba toxins. Toxicon, 1995, 33, 459-474.	1.6	11
195	Metabolism of sodium oestrone [35S]sulphate in the guinea pig. Biochemical Journal, 1972, 128, 347-352.	3.1	10
196	Elegance persists in the purification of K+ channels. Biochemical Journal, 1989, 264, 623-624.	3.7	9
197	Intrinsic voltage dynamics govern the diversity of spontaneous firing profiles in basal forebrain noncholinergic neurons. Journal of Neurophysiology, 2012, 108, 406-418.	1.8	9
198	A Rational Design of a Selective Inhibitor for Kv1.1 Channels Prevalent in Demyelinated Nerves That Improves Their Impaired Axonal Conduction. Journal of Medicinal Chemistry, 2017, 60, 2245-2256.	6.4	9

#	Article	IF	Citations
199	Position-dependent attenuation by Kv1.6 of N-type inactivation of Kv1.4-containing channels. Biochemical Journal, 2011, 438, 389-396.	3.7	8
200	Conjugate of an IgG Binding Domain with Botulinum Neurotoxin A Lacking the Acceptor Moiety Targets Its SNARE Protease into TrkA-Expressing Cells When Coupled to Anti-TrkA IgG or Fc-Î ² NGF. Bioconjugate Chemistry, 2017, 28, 1684-1692.	3.6	8
201	Neuronal entry and high neurotoxicity of botulinum neurotoxin A require its N-terminal binding sub-domain. Scientific Reports, 2017, 7, 44474.	3.3	8
202	Antigenic similarities between the subunits of acetylcholine receptor fromTorpedo marmorata. FEBS Letters, 1982, 141, 1-5.	2.8	7
203	Actions of \hat{l}^2 -bungarotoxin on spontaneous release of transmitter at muscle end-plates treated with botulinum toxin. Toxicon, 1986, 24, 123-130.	1.6	7
204	Biochemical and electrophysiological properties of antibodies against pure acetylcholine receptor from vertebrate muscles and its subunits from Torpedo in relation to experimental myasthenia. Neurochemistry International, 1983, 5, 445-458.	3.8	6
205	Lack of detectable ADP-ribosylation in synaptosomes associated with inhibition of transmitter release by botulinum neurotoxins A and B. Biochemical Society Transactions, 1988, 16, 883-884.	3.4	6
206	Involvement of a Glutamatergic Mechanism in \hat{l} -Dendrotoxin-Induced Hippocampal Neuronal Cell Loss in the Rat. Basic and Clinical Pharmacology and Toxicology, 2004, 94, 132-138.	2.5	6
207	Clues to the multi-phasic inhibitory action of botulinum neurotoxins on release of transmitters. Journal De Physiologie, 1990, 84, 237-46.	0.2	6
208	Characterization of Acetylcholine-Receptor Protein from Skeletal Muscle. Biochemical Society Transactions, 1977, 5, 168-170.	3.4	5
209	Relationship of acceptors for botulinum neurotoxins (types A and B) in rat CNS with the cholinergic marker, chol-l. Neurochemistry International, 1988, 13, 25-36.	3.8	5
210	ADP-ribosylation of cerebrocortical synaptosomal proteins by cholera, pertussis and botulinum toxins. Toxicon, 1990, 28, 963-973.	1.6	5
211	New inhibitors of the $Kv\hat{l}^22$ subunit from mammalian $Kv1$ potassium channels. International Journal of Biochemistry and Cell Biology, 2014, 55, 35-39.	2.8	5
212	Neurobiology and therapeutic utility of neurotoxins targeting postsynaptic mechanisms of neuromuscular transmission. Drug Discovery Today, 2019, 24, 1968-1984.	6.4	5
213	Substrate specificity of mammalian intestinal dipeptidases and tripeptidases. Biochemical Journal, 1969, 111, 30P-30P.	3.1	4
214	Action of antibodies directed against the acetylcholine receptor on channel function at mouse and rat motor end-plates Journal of Physiology, 1988, 399, 577-589.	2.9	4
215	Action of botulinum neurotoxin A on protein phosphorylation in relation to blockade of transmitter release. Biochemical Society Transactions, 1988, 16, 885-886.	3.4	4
216	Action of αâ€dendrotoxin on K ⁺ currents in nerve terminal regions of axons in rat olfactory cortex. British Journal of Pharmacology, 1993, 109, 535-538.	5.4	4

#	Article	IF	CITATIONS
217	Expression and Characterisation of the Heavy Chain of Tetanus Toxin: Reconstitution of the Fully-Recombinant Dichain Protein in Active Form. Journal of Biochemistry, 1999, 125, 1200-1208.	1.7	4
218	Antibodies against purified acetylcholine receptor from denervated muscle differentiate sub- and extra-synaptic forms of the receptor. Toxicon, 1979, 17, 36.	1.6	3
219	Roles of the constituent chains of botulinum neurotoxin type A in the blockade of neuromuscular transmission in mice. Biochemical Society Transactions, 1988, 16, 886-887.	3.4	3
220	Fusion of Golgiâ€derived vesicles mediated by <scp>SNAP</scp> â€25 is essential for sympathetic neuron outgrowth but relatively insensitive to botulinum neurotoxins <i>inÂvitro</i> . FEBS Journal, 2014, 281, 3243-3260.	4.7	3
221	Engineering of botulinum neurotoxins as novel therapeutic tools. , 2015, , 995-1015.		3
222	Low-Affinity Neurotrophin Receptor p75 Promotes the Transduction of Targeted Lentiviral Vectors to Cholinergic Neurons of Rat Basal Forebrain. Neurotherapeutics, 2016, 13, 859-870.	4.4	3
223	Application of specifically acting toxins to the detection of functional components common to peripheral and central synapses. Advances in Cytopharmacology, 1979, 3, 409-34.	0.3	3
224	Tritiation of \hat{l}^2 -bungarotoxin and its saturable binding to membranes of cerebrocortical synaptosomes. Biochemical Society Transactions, 1982, 10, 386-387.	3.4	2
225	Effects of botulinum neurotoxin and Lambert-Eaton myasthenic syndrome IgG at mouse nerve terminals. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1989, 1, 229-242.	1.2	2
226	Molecular Definition of Neuronal Targets for Novel Neurotherapeutics: SNAREs and Kv1 Channels. NeuroToxicology, 2005, 26, 753-760.	3.0	2
227	Substrate profiling and aldehyde dismutase activity of the $\text{Kv}\hat{l}^22$ subunit of the mammalian Kv1 potassium channel. International Journal of Biochemistry and Cell Biology, 2010, 42, 2012-2018.	2.8	2
228	Peptide Toxins that Alter Neurotransmitter Release. , 1994, , 681-717.		2
229	Molecular heterogeneity of human intestinal peptidases from control subjects and children with treated and untreated coeliac disease. Biochemical Journal, 1970, 119, 7P-8P.	3.1	1
230	Metabolism of sodium oestrone [35S] sulphate in the rat. Biochemical Journal, 1970, 119, 22P-22P.	3.1	1
231	Mechanistic basis for the therapeutic effectiveness of botulinum toxin A on over-active cholinergic nerves. , 0, , 9-26.		1
232	Royal academy of medicine in Ireland section of biological sciences. Irish Journal of Medical Science, 1968, 1, 35-36.	1.5	0
233	Action of pure \hat{I}^2 -bungarotoxin on cholinergic synapses in vitro. Toxicon, 1979, 17, 174.	1.6	0
234	Monoclonal antibodies as probes for acetylcholine receptors. Biochemical Society Transactions, 1985, 13, 424-424.	3.4	0

#	Article	IF	CITATIONS
235	A simple method for recording single-channel activity from synaptic plasma membranes. Journal of Neuroscience Methods, 1993, 49, 81-91.	2.5	O
236	Crystallization and preliminary X-ray analysis of pseudo-merohedrally twinned crystals of the full-length \hat{I}^2 2subunit of the Kv1 K+channel fromRattus norvegicus. Acta Crystallographica Section D: Biological Crystallography, 2004, 60, 912-914.	2.5	0
237	Pharmacology of Botulinum Neurotoxins: Exploitation of Their Multifunctional Activities as Transmitter Release Inhibitors and Neuron-Targeted Delivery Vehicles. , 2014, , 9-33.		O
238	Oligomeric and Subunit Structures of Voltage-Gated Potassium Channels. Medical Science Symposia Series, 1995, , 17-22.	0.0	0